Thiazolidinediones (glitazones)

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.